Radiation for Triple-Negative Breast Cancer: 84 Real Stories

84 stories match breast cancer, triple-negative and radiation. 82 of them mention surgery.

Cancer Stories

Erica, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Erica's Survivor Story

Patient Info: Erica Watson, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative

As of October 2024, Erica had no evidence of disease after triple-negative breast cancer showed a complete response to 16 chemotherapy treatments, lumpectomy, reconstructive surgery and 15 rounds of radiation.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to immunotherapy combination

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: ER-negative; PR-negative; HER2-negative; Ki-67 >80%

Metastatic Site: left lung, neck lymph nodes, mediastinal lymph nodes

Metastatic triple-negative breast cancer had a partial response after 9 months of pembrolizumab plus MK-4830, with reduced tumor burden, decreased lung and mediastinal metastases, and no new metastatic lesions; immunotherapy continued after prednisone controlled a grade 2 lichenoid eruption.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV triple-negative breast cancer in remission: CBD and exercise for neuropathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative breast cancer. Blood and immune inflammation measures were tracked during neuropathy care.

Metastatic Site: liver

She was in remission for more than 5 years after Stage IV breast cancer with a solitary liver metastasis, while later managing chemotherapy-induced peripheral neuropathy with CBD and an exercise program that improved symptoms and function.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Secretory breast cancer: mastectomy and radiotherapy to no evidence of disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 50%; tumor-infiltrating lymphocytes 60%

As of May 2024, 6 months after mastectomy and adjuvant radiotherapy for pT2N0M0 triple-negative secretory breast cancer, clinical examination and imaging showed no evidence of relapse.

PubMed Central
OutcomeCancer-Free / NED
Samantha, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Samantha's Survivor Story

Patient Info: Samantha Salway, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of May 2024, Samantha had delivered a healthy baby, completed chemotherapy, lumpectomy, radiation and additional chemotherapy, had no current evidence of cancer, and remained under close monitoring.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed Central
OutcomeCare Ongoing
Dorian, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story

Patient Info: Dorian de Salvo, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of March 2024, Dorian had a complete response to TCHP chemotherapy, clear surgical margins, and no lymph-node involvement after surgery, with radiation completed and additional care still expected for several months.

The Patient Story
OutcomeCancer-Free / NED
Chantal, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Chantal's Survivor Story

Patient Info: Chantal, Female, Under 40 | Stage II

Biomarkers: Triple-negative breast cancer; BRCA1 mutation

As of December 2023, Chantal reported that she did not currently have cancer, was followed by medical oncology every 3-4 months, and used Signatera testing because tumor markers were not reliable for her.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Treatment-Refractory Triple-Negative Breast Cancer Treated With Tumor-Infiltrating Lymphocytes

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Germline BRCA1 pathogenic variant; later triple-negative phenotype

Metastatic Site: skin, lungs, bones

Tumor burden briefly decreased after tumor-infiltrating lymphocyte therapy, but she developed severe treatment complications followed by rapid cancer relapse and died about 1 month after the TIL/IL-2 treatment began.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Adenoid Cystic Breast Cancer Spreads to the Kidney, Lungs, Bone and Spleen

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: Triple-negative

Metastatic Site: kidneys, lungs, spleen, bone, lymph nodes

The cancer progressed from an initial kidney metastasis to widespread disease involving the lungs, spleen, right kidney, lymph nodes, and C4 vertebra. By May 2022 she had worsening cachexia and pain, and best supportive care was recommended.

PubMed Central
OutcomeSetback / Progression
April, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: April's Patient Story

Patient Info: April Donaldson, Female, 40s | Stage IV

Biomarkers: Triple-negative breast cancer; BRCA1 positive

Metastatic Site: Lungs

As of September 2023, April was living with Stage IV metastatic triple-negative breast cancer in the lungs; scans were stable in February but showed growth again in July, and PARP inhibitor therapy was being planned.

The Patient Story
OutcomeSetback / Progression
Kelly, who was diagnosed with Stage III Breast CancerBreast Cancer

Kelly's Stage 3 Breast Cancer Story: “I’m Still Here & THRIVING!"

Patient Info: Kelly Thomas, Female, Under 40 | Stage III

Biomarkers: Initial triple-negative breast cancer; after surgery

As of August 2023, Kelly was 5 years from her Stage IIIC triple-negative breast cancer diagnosis with no recurrence reported.

The Patient Story
OutcomeCancer-Free / NED
Susan, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Susan's Patient Story

Patient Info: Susan, Female, 70+

Biomarkers: BRCA negative; earlier breast cancer described as triple-negative; later breast cancer estrogen-positive and progesterone-positive; HER2 not reported

As of August 2023, Susan was living after multiple breast cancer diagnoses, including a later estrogen-positive/progesterone-positive non-metastatic breast cancer treated with bilateral mastectomy and ongoing 5-year estrogen-blocker therapy.

The Patient Story
OutcomeCare Ongoing
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
Lucy, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy E., Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

As of January 2023, Lucy had been told she was all-clear/cancer-free after chemotherapy, had undergone double mastectomy with staged reconstruction planning, and was continuing close oncology reviews every 3-4 months.

The Patient Story
OutcomeCancer-Free / NED
Stephanie, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative; genetic testing negative

As of October 2022, Stephanie had completed treatment for triple-negative breast cancer in January 2022, follow-up tests showed she was cancer-free, and she had no evidence of cancer.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Reclassified After NTRK Fusion Testing

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ETV6-NTRK3 fusion detected in tissue but not circulating tumor DNA; ER low-positive; PR-negative; HER2-negative; PD-L1-negative; germline CHEK2 variant of uncertain significance

Metastatic Site: lungs and pleura; hilar, mediastinal and retrocaval…

After tissue testing identified an ETV6-NTRK3 fusion, treatment with larotrectinib produced a rapid clinical and radiological response.

PubMed Central
OutcomeResponding Well